OVID - Ovid Therapeutics Inc

Ovid Therapeutics Inc., a biopharmaceutical company, develops impactful medications for patients and families with neurological disorders in the United States. The company is headquartered in New York, New York.

52W High

$1.47

52W Low

$0.24

MA Status:

50D: Below 200D: Below

Beta (~1 neutral, <0.9 lower risk)

0.36

Valuation

Attractive

As of 2025-06-30 (Overview)

Trailing P/E (<15 better)

N/A

Forward P/E (<15 better)

1.79

EV/EBITDA (<8 favorable)

-0.69

EV/Revenue (<3 favorable)

9.50

P/S (TTM) (<3 favorable)

13.15

P/B (<3 favorable)

1.57

Ownership

Balanced

Source: Overview

Insiders (1–5% typical)

16.31%

Institutions (25–75% balanced)

34.69%

Shares Outstanding

71,110,000

Float

59,524,000

Dividend Yield (2–6% sweet spot)

N/A

Ex‑Dividend Date

N/A

Income & Growth

Profitability: Weak

As of 2025-06-30 (Overview)

Revenue (TTM)

6,651,000

Gross Profit (TTM)

6,651,000

EPS (TTM)

-0.54

Profit Margin (>10% good)

N/A

Operating Margin (TTM) (higher better)

-0.81%

ROE (TTM) (>15% strong)

-0.53%

EPS YoY (Quarterly) (>10% good)

N/A

Revenue YoY (Quarterly) (>8% good)

36.11

Momentum

Bearish momentum

Value

0.1656

0.1746

Trend

Falling

Signal Cross

No cross

As of

Sep. 12, 2025